Organoids point to therapy for aggressive, rare ovarian cancer

Date:
Maxima, organoids, microscoop

Lab-developed 3D mini-tumors point to a possible new treatment for a very rare, aggressive form of ovarian cancer. Researchers from the Clevers group e.t. grew the tumor organoids and tested them for 153 active compounds from existing drugs. The study shows that organoids can help determine treatment strategies for this and other rare cancers.

    • SCCOHT organoids have been grown in the lab for the first time
    • Drug screening with organoids indicate methotrexate as an effective and selective candidate for the treatment of SCCOHT
    • Future studies and discussions are needed to determine whether methotrexate can become a standard part of therapy for these children

    Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a very rare form of childhood cancer that occurs in girls and young women. Only a few children with SCCOHT have been treated for this since the opening of the Princess Máxima Center. No standard treatment is currently in place, and the cure rate is low at 10 to 20%. Research into new, better treatments is therefore important. But because of the very limited research material, this has previously been difficult.

    In search of an effective drug

    Researchers from the Clevers group e.t.  at the Princess Máxima Center have succeeded in growing SCCOHT organoids. This allowed them to test the effect of 153 pediatric oncology drugs on tumor cells. From the tests, methotrexate appeared as an effective and selective drug.

    Today, the results of the study led by Prof. Dr. Hans Clevers, former research group leader at the Princess Máxima Center and Oncode Investigator, were published in Science Advances. Stichting Kinderen Kankervrij (KiKa), Oncode Institute and Oncode Accelerator made this research possible.

    The SCCOHT organoids are a good example of the type of organoids that will be included in the Central Máxima Organoid Biobank (CMOB). These organoids can eventually be requested by researchers from both inside as well as outside the Máxima, which will increase and improve pediatric cancer research worldwide.

    Recapulating

    The researchers used tumor material from three children with SCCOHT to grow mini tumors in the lab. This tumor material came from the biobank of the Máxima. Seok-Young Kim, PhD candidate in the Clevers group e.t. and first author succeeded together with his colleagues in growing the organoids. He says: ‘We were able to culture eight different organoid lines from the eight tumor samples available in the biobank. These were from three children. Analyses show that the cultured organoids reflect the original tumor tissue, both on a genetic and transcriptomic level.’

    In the high-throughput screening facility at the Máxima Center, the organoids were then exposed to 153 different active substances from drugs already used within pediatric oncology. Kim: ‘We saw that methotrexate was the most effective and selective drug in the library, even when compared to the drugs that are used to treat SCCOHT patients.’

    Prof. Dr. Hans Clevers, pioneer in the field of organoids: ‘This research shows that organoids can help determine treatment strategies for this and other rare cancers.’

    Clinical application

    Currently, there is no standard treatment for SCCOHT available. The very small number of patients, children and young adults, makes setting up clinical trials complex.

    Dr. Jozsef Zsiros, pediatric oncologist at the Máxima Center and involved in the study: ‘The results in the lab are very promising. Together with colleagues from other research hospitals, I will discuss the next steps for clinical application to determine whether methotrexate can become a standard part of therapy. Because methotrexate is already used in pediatric oncology and the survival rate of SCCOHT patients is low, we will assess, for example, whether methotrexate is appropriate on a child-by-child basis. This way we would learn whether this finding can increase the survival rate of this rare, aggressive ovarian cancer.’

Nieuwe kassen Botanische Tuinen Universiteit Utrecht

Design and start of construction for new greenhouses at the Botanical Gardens announced

The design for the new greenhouse complex of the Botanical Gardens has been finalized, the construction partners have been selected and preparations for construction will start in November 2026. This brings the realization of the new complex one step closer. Construction is scheduled for spring 2027.

Senior civil servants from the Ministries of Economic Affairs and Climate Policy (EZK) and Health, Welfare and Sport (VWS) visit Utrecht Science Park to exchange knowledge on improving prevention, healthcare and economic earning capacity.

How can we ensure that innovations reach patients more effectively and quickly, while also contributing to the Netherlands’ future earning capacity? This question was at the heart of a visit by senior civil servants from the Ministry of Economic Affairs and Climate Policy and the Ministry of Health, Welfare and Sport to Utrecht Science Park on Friday, 30 October.

2.5-hectare new nature reserve at Utrecht Science Park opened

In an area where education, healthcare, housing and research compete for space, 2.5 hectares – equivalent to seven football pitches – of new nature has been created. A 1.6-kilometre-long ‘green corridor’ connects Utrecht Science Park with the surrounding nature reserves, enhances biodiversity and makes the area more attractive to plants and animals.

His Majesty the King visits large-scale exercise at the Major Incident Hospital at Utrecht Science Park: prepared together for major emergencies

On Saturday, October 31, a large-scale exercise took place at the Major Incident Hospital at the Utrecht Science Park. During the exercise, dubbed “Dubbelspoor” (Dual Track), the Major Incident Hospital had to respond to two major incidents almost simultaneously. In Amersfoort, a train carrying thirty injured Dutch military personnel arrived. At nearly the same time, a coach plowed into a crowd during a Halloween celebration. His Majesty the King also visited both locations, marking the 35th anniversary of the Major Incident Hospital.